Anti-VEGF therapy is appealing in cervical cancer with upregulation of VEGF-A and VEGF receptor 1 seen in cases of recurrent disease [69] and addition of bevacizumab (anti-VEGF-A) to chemotherapy is currently first line standard of care for recurrent/metastatic cervical cancer in view of reported survival benefit over chemotherapy alone [7]. This evidence concerns the gene VEGFA and cervical carcinoma.